IN2012DN00549A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00549A
IN2012DN00549A IN549DEN2012A IN2012DN00549A IN 2012DN00549 A IN2012DN00549 A IN 2012DN00549A IN 549DEN2012 A IN549DEN2012 A IN 549DEN2012A IN 2012DN00549 A IN2012DN00549 A IN 2012DN00549A
Authority
IN
India
Prior art keywords
subject
activity
relates
compounds
hif levels
Prior art date
Application number
Other languages
English (en)
Inventor
Kang Xinshan
Long Wei
Ma Cunbo
Wang Yanping
Cao Hong
Wang Yinxiang
Tan Fenlai
Hu Yunyan
Original Assignee
Zhejiang Beta Pharma Inc
Kang Xinshan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Beta Pharma Inc, Kang Xinshan filed Critical Zhejiang Beta Pharma Inc
Publication of IN2012DN00549A publication Critical patent/IN2012DN00549A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
IN549DEN2012 2009-07-15 2010-07-14 IN2012DN00549A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910089274 2009-07-15
PCT/CN2010/001057 WO2011006355A1 (en) 2009-07-15 2010-07-14 Compounds as hypoxia mimetics, and compositions, and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00549A true IN2012DN00549A (ja) 2015-06-12

Family

ID=43448908

Family Applications (1)

Application Number Title Priority Date Filing Date
IN549DEN2012 IN2012DN00549A (ja) 2009-07-15 2010-07-14

Country Status (14)

Country Link
US (1) US8742138B2 (ja)
EP (1) EP2454249B1 (ja)
JP (1) JP5847710B2 (ja)
KR (1) KR20120065311A (ja)
CN (1) CN102164905B (ja)
AU (1) AU2010273101B2 (ja)
CA (1) CA2767911C (ja)
ES (1) ES2702524T3 (ja)
HK (1) HK1161234A1 (ja)
IL (1) IL217531A0 (ja)
IN (1) IN2012DN00549A (ja)
SG (1) SG177598A1 (ja)
WO (1) WO2011006355A1 (ja)
ZA (1) ZA201200293B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2842730C (en) 2011-07-22 2018-08-21 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US9238637B2 (en) * 2011-07-29 2016-01-19 Beijing Betta Pharmaceuticals Co., Ltd Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
US20160193238A1 (en) * 2015-01-05 2016-07-07 National Cancer Center HNF4-alpha ANTAGONIST AND USE THEREOF
CN113694077A (zh) 2015-08-13 2021-11-26 索马根尼科斯公司 用于伤口愈合的短小发夹rna与微rna的组合物以及方法
WO2018205928A1 (zh) 2017-05-09 2018-11-15 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080649A2 (en) 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
JP2009506068A (ja) * 2005-08-25 2009-02-12 エモリー・ユニバーシティ Ｈｉｆ阻害剤
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
ES2446416T3 (es) 2005-12-09 2014-03-07 Amgen, Inc. Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos
TW200808793A (en) * 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
EP2134720B1 (en) * 2007-03-29 2010-10-13 Novartis AG Heterocyclic spiro-compounds
US8324405B2 (en) * 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
EP2341904A1 (en) * 2008-08-26 2011-07-13 Fibrogen, Inc. Methods for treatment of multiple sclerosis

Also Published As

Publication number Publication date
US20120172399A1 (en) 2012-07-05
EP2454249B1 (en) 2018-09-19
JP2012532897A (ja) 2012-12-20
US8742138B2 (en) 2014-06-03
WO2011006355A1 (en) 2011-01-20
EP2454249A1 (en) 2012-05-23
EP2454249A4 (en) 2012-12-12
ES2702524T3 (es) 2019-03-01
JP5847710B2 (ja) 2016-01-27
KR20120065311A (ko) 2012-06-20
AU2010273101A1 (en) 2012-02-02
IL217531A0 (en) 2012-02-29
AU2010273101B2 (en) 2016-02-25
CN102164905A (zh) 2011-08-24
SG177598A1 (en) 2012-02-28
CN102164905B (zh) 2014-04-30
CA2767911C (en) 2016-03-29
CA2767911A1 (en) 2011-01-20
HK1161234A1 (en) 2012-08-24
AU2010273101A2 (en) 2012-03-15
ZA201200293B (en) 2012-09-26

Similar Documents

Publication Publication Date Title
IN2014DN09782A (ja)
IN2012DN00624A (ja)
IN2015DN00438A (ja)
IN2014DN05986A (ja)
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
JO3300B1 (ar) مركبات وتركيبات لتعديل نشاط egfr
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
TW201611843A (en) Methods of treatment with arginine deiminase
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
IN2012DN00549A (ja)
MX341308B (es) Método para prevenir inflamación.
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
EA201390876A1 (ru) Соединения, ингибирующие металлоферменты
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
WO2010117727A3 (en) Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
NZ705406A (en) Use of attenuated strains of toxoplasma for the prevention or treatment of cryptosporidiosis
MY173722A (en) Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome
MX2010004814A (es) Metodos para tratar esclerodermia.
AU2013328979A8 (en) Compounds for treating Rac-GTPase mediated disorder